Economic Indicators - The JOLTS report is expected to show steady job openings at 7.7 million, indicating a healthy jobs market despite some cooling [2] - Private-sector payrolls are projected to increase by over 40K month over month to 120K, while non-farm payrolls are expected to decrease to 128K from 151K [2] - Initial and Continuing Jobless Claims have remained stable, suggesting a well-off labor market, but there are concerns about potential increases due to layoffs and immigration policies [3] Trade Policies - President Trump announced that trade tariffs will begin on April 2nd for "all countries," contrary to earlier expectations that only countries with trade imbalances would be affected [4] - The implementation of tariffs is seen as a strategy to fund corporate tax cuts [4] Market Performance - The Nasdaq index has declined nearly 15% from its highs 5.5 weeks ago, with the small-cap Russell 2000 down over 19% [5] - The Dow, S&P 500, and Nasdaq are all experiencing significant declines, with the Dow down 267 points, S&P 500 down 51 points, and Nasdaq down 238 points [5] Earnings Reports - Notable companies reporting earnings this week include PVH, RH, and Guess?, with Delta Air Lines and major banks like JPMorgan and Wells Fargo set to report later [7]

Core Viewpoint - Eli Lilly plans to invest $27 billion to construct four new manufacturing plants in the United States, responding to potential drug import duties from the Trump administration [1][4]. Investment and Job Creation - The investment is expected to create 3,000 high-skilled positions and approximately 10,000 construction jobs [2]. - The new manufacturing sites will be announced later this year and are anticipated to be operational within five years [3]. Industry Context and Government Relations - This investment aligns with the Trump administration's push for revitalizing American manufacturing, following a $500 billion investment announcement by Apple [3]. - Eli Lilly's CEO emphasized the need for the extension or improvement of corporate tax cuts to support the investment, highlighting that the company had not built a new site in the US for over 40 years prior to the first set of tax cuts [4]. Market Response and Stock Performance - Shares of Eli Lilly rose by approximately 0.5% to $906.70, with the stock increasing over 16% since the beginning of the year [7]. Supply Chain Considerations - A significant portion of the pharmaceutical industry's supply chain relies on overseas production, particularly from countries like Ireland, Switzerland, and China for active pharmaceutical ingredients [7][10]. - Indian firms also play a crucial role in producing lower-cost generic medications [8]. Ongoing Negotiations - Eli Lilly is currently negotiating with multiple states regarding the placement of its new manufacturing facilities and is open to additional proposals until mid-March [12]. Previous Investments - This commitment follows a $23 billion investment in US operations from 2020 to 2024, which included new manufacturing sites in Wisconsin and North Carolina, as well as expansions in Indiana [13].